Topics
Diffuse midline glioma | Treatment | Targeted therapy | Paxalisib
Home > Publications > Topics > Diffuse midline glioma > Treatment > Targeted therapy > Paxalisib
Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ,
Mannan A, Staudt DE, Thomas BC, Germon ZP, Laternser S, Kearney
PS, Jamaluddin MFB, Douglas AM, Beitaki T, McEwen HP, Persson ML,
Hocke EA, Jain V, Aksu M, Manning EE, Murray HC, Verrills NM, Sun
CX, Daniel P, Vilain RE, Skerrett-Byrne DA, Nixon B, Hua S, de
Bock CE, Colino-Sanguino Y, Valdes-Mora F, Tsoli M, Ziegler DS,
Cairns MJ, Raabe EH, Vitanza NA, Hulleman E, Phoenix TN, Koschmann
C, Alvaro F, Dayas CV, Tinkle CL, Wheeler H, Whittle JR, Eisenstat
DD, Firestein R, Mueller S, Valvi S, Hansford JR, Ashley DM,
Gregory SG, Kilburn LB, Nazarian J, Cain JE, Dun MD.
PI3K/mTOR
is a therapeutically targetable genetic dependency in diffuse
intrinsic pontine glioma.
J
Clin Invest. 2024 Feb 6;134(6):e170329. doi:
10.1172/JCI170329. PMID:
38319732. Laboratory investigation. ˍ
RELATED
ARTICLE
Tzaridis T, Wechsler-Reya RJ.
Just
a spoonful of metformin helps the medicine go down.
J
Clin Invest.
2024 Mar 15;134(6):e179144. doi:
10.1172/JCI179144. PMID:
38488006. Comment. ˍ